Press release from PR Newswire
ALLERGAN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Allergan, Inc.
Tuesday, April 22, 2014
ALLERGAN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Allergan, Inc.22:24 EDT Tuesday, April 22, 2014
NEW ORLEANS, April 22, 2014 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Allergan, Inc. ("Allergan" or the "Company") (NYSE: AGN) to Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX). Under the terms of the proposed transaction, shareholders of Allergan would receive only $48.30 in cash and 0.83 shares of Valeant common stock for each share of Allergan common stock that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (firstname.lastname@example.org) or associate Michael J. Palestina (email@example.com) toll free at any time at 855-768-1857.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC206 Covington St.Madisonville, LA 70447
SOURCE Kahn Swick & Foti, LLC